Press Releases

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab (Rituxan®) and lenalidomide (Revlimid®), along with epcoritamab (Epkinly®) — works better than using the two drugs alone. The findings were presented at the American Society of Hematology Annual Meeting (ASH) on December 7, 2025. The findings were also published in The Lancet.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:Omar Abdel-Wahab Elected to the National Academy of ...

Memorial Sloan Kettering Cancer Center (MSK) will award three influential cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.

Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to Newsweek’s World’s Best Specialized Hospitals 2026 list.

Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has been elected to the National Academy of Medicine (NAM), one of the most prestigious honors in the fields of health and medicine.

Memorial Sloan Kettering Cancer Center (MSK) announced today that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). A renowned physician-scientist, Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:Maria Jasin Awarded the 2025 Peral Meister Greengard...

Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading institutions for cancer treatment, research, and education, and Quantoom Biosciences, a full-stack RNA technology partner have executed a non-exclusive research license and supply agreement to support the development of personalized cancer therapies using Quantoom’s proprietary lipid nanoparticle (LNP) formulation technology, Ncapsulate® QCX-002.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Matthew Bott Joins the Lung Cancer Research Fo...